Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 16, 2008

View Archived Issues

SVV-001 studied in experimental medulloblastoma in mice

Renovo presents results from Juvista and Zesteem trials

Rigel presents preclinical data on novel JAK2 inhibitor R-723

Qnexa meets primary endpoint in 28-week EQUATE study

Xoma provides preclinical animal data for diabetes drug XOMA-052

Valeant to acquire Dow Pharmaceutical Sciences for USD 285 million

IDMC recommends continuation of Seattle Genetics' phase IIb trial of lintuzumab in AML

Pharmacokinetic data for retigabine therapy disclosed

Nile presents results from phase Ib safety and PK study of CD-NP

Nuvelo reports encouraging results from phase I NU-206 trial in healthy volunteers

Phase III data show paliperidone's efficacy and tolerability in schizophrenia

PolyMedix announces positive phase I PMX-30063 data

ZymoGenetics reports favorable phase IIIb Recothrom results

Amylin, Lilly and Alkermes present update on DURATION clinical program for Byetta

FDA approves Pegintron/Rebetol combination in pediatric HCV patients

German regulatory authority approves CureVac's CTA to initiate phase I clinical study of CV-9103

SkyePharma and Somnus successfully complete phase I trial of SKP-1041 for sleep maintenance

Affiris initiates preclinical development of Parkinson's vaccine PD-01

Galmed successfully completes phase I trial of aramchol for fatty liver disease

Santhera completes recruitment into phase III MICONOS trial of SNT-MC17

Responses seen with afutuzumab in patients with CD20+ non-Hodgkin's lymphoma

TG-101348 appears well tolerated, decreases spleen size in myelofibrosis patients

Abraxis BioScience launches Abraxane in the European Union

Novel therapeutic agents for GERD disclosed in recent AstraZeneca patent

New antidiabetic agents disclosed in recent Merck Frosst patent

Recent Roche patent reports new agents for obesity

Rigel presents clinical data on fostamatinib disodium in B-cell NHL

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 15, 2026.
Microbiota modulates the antidepressant effects of GLP-1 analogues
BioWorld Science
Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...
EHA 2026: With new lenses, a changing view on pediatric cancers
BioWorld
In the most simplistic view, adult cancers occur because “immature cells are exposed to mutagens, accumulate mutations, and across life ultimately transform into...
Enliven’s phase I CML data Enable phase III with BCR/ABL1 bid
BioWorld
Tolerability is a key factor in the appeal of Enliven Therapeutics Inc.’s ELVN-001 for previously treated chronic myeloid leukemia (CML), which yielded positive...